Why do some tumors spread while others remain localized? The mechanisms governing the metastatic potential of tumor cells ...

Castle Biosciences to Share Data Reinforcing the Clinical Value of Its Dermatologic Portfolio of Gene Expression Profile Tests at the 22nd Annual Winter Clinical Dermatology Conference - Hawaii® ...

State Key Laboratory of Gene Expression, Westlake University has the following research output in the current window (1 October 2024 - 30 September 2025) of the Nature Index. Click on Count to view a ...

FRIENDSWOOD, Texas--(BUSINESS WIRE)--Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today provided an update on its test ...

Across primary sites, histological subtypes, and mitotic count categories, clinicopathological factors and gene-expression profile results were consistent for discriminating SLN positivity rates.

Using genomic and transcriptional data has greatly improved the understanding of multiple aspects of human physiology. A new paper in PNAS reports on molecular-level associations of co-occurring ...

Castle Biosciences (CSTL) provided an update on its test currently in development for use in patients diagnosed with moderate-to-severe atopic dermatitis, or AD, who are seeking systemic treatment.

18F-PSMA-1007 PET/CT for response assessment in patients with metastatic renal cell carcinoma undergoing first line tyrosine kinase or checkpoint inhibitor therapy.

Solid Biosciences is approaching key catalysts in DMD gene therapy, with SGT-003 showing promising early safety and efficacy signals. The evolving DMD landscape, especially safety concerns with ...

As we age, we don't recover from injury or illness like we did when we were young. But new research from UCSF has found gene regulators—proteins that turn genes on and off—that could restore the aging ...

What do your genes have to do with growing old? Quite a lot. But is it due to the actual DNA, or the way those genes are expressed? KPBS sci-tech reporter Thomas Fudge has more on new research that ...